Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo controlled study to investigate the safety and tolerability and clinical activity of 28 days of oral repeat dosing With GW856553 at 7.5mg BID in subjects with active rheumatoid arthritis on stable anti-rheumatic therapy

Next Previous
Trial Profile

A randomized, double blind, placebo controlled study to investigate the safety and tolerability and clinical activity of 28 days of oral repeat dosing With GW856553 at 7.5mg BID in subjects with active rheumatoid arthritis on stable anti-rheumatic therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Losmapimod (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 11 May 2008 The expected completion date for this trial is now 1 Jan 2008.
    • 11 May 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Jun 2007 Status changed from initiated to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top